(MedPage Today) — HOUSTON — Adding an investigational nonsteroidal mineralocorticoid receptor antagonist (MRA) to an SGLT2 inhibitor led to a superior reduction in albuminuria among chronic kidney disease patients at risk for kidney failure…
Source link : https://www.medpagetoday.com/meetingcoverage/asn/118439
Author :
Publish date : 2025-11-11 15:58:00
Copyright for syndicated content belongs to the linked Source.
